Estatísticas Básicas
| LEI | 549300BWL6XZSU0ZFR32 |
| CIK | 1671502 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Quoin Pharmaceuticals, Ltd. - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Esta página fornece uma lista completa e cronológica de Arquivamentos da SEC, excluindo os arquivamentos de propriedade que fornecemos em outro lugar.
| June 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2026 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commission |
|
| June 4, 2026 |
Exhibit 99.1 Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome -Designation provides regulatory and development incentives in Japan, including up to 10 years of market exclusivity upon approval- -Follows Orphan Drug Designation, Pediatric Rare Disease Designation, and Fast Track Designation previously granted by the U.S. FDA, and Orphan Dr |
|
| June 2, 2026 |
10,045,455 American Depositary Shares Representing 351,590,925 Ordinary Shares Filed pursuant to Rule 424(b)(3) Registration No. 333-291385 PROSPECTUS SUPPLEMENT NO. 1 (to Prospectus dated December 4, 2025) 10,045,455 American Depositary Shares Representing 351,590,925 Ordinary Shares This Prospectus Supplement No. 1 supplements the prospectus dated December 4, 2025 (the “Prospectus”) relating to the resale from time to time of up to 10,045,455 American Depositary Shares (“A |
|
| May 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2026 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commission |
|
| May 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37846 QUOIN PHARMACEUTICALS LTD. |
|
| May 7, 2026 |
Exhibit 99.1 Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results – Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003 in Netherton Syndrome – Submitted Application to Japanese MHLW for Orphan Drug Designation (ODD) for QRX003; MHLW Confirmed QRX003 Qualifies for Both Orphan Drug Designation and Fast Track Review – U.S. FDA Gra |
|
| March 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2026 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissi |
|
| March 26, 2026 |
Exhibit 10.3 Annex A QUOIN PHARMACEUTICALS LTD. Compensation Policy for Executive Officers and Directors (As Adopted by the Shareholders on, 2025) A-1 Table of Contents A. Overview and Objectives A-2 B. Base Salary and Benefits A-3 C. Cash Bonuses A-5 D. Equity Based Compensation A-6 E. Retirement and Termination of Service Arrangements A-7 F. Exculpation, Indemnification and Insurance A-8 G. Arra |
|
| March 26, 2026 |
Exhibit 4.17 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of the date of this Annual Report on Form 10-K, Quoin Pharmaceuticals, Ltd., an Israeli company (“we,” “our” and the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: American Depositary |
|
| March 26, 2026 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37846 QUOIN P |
|
| March 26, 2026 |
Exhibit 21.1 LIST OF SUBSIDIARIES Quoin Pharmaceuticals Inc. Quoin Therapeutics (Ireland) Limited |
|
| March 26, 2026 |
Exhibit 99.1 Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results – Closes Private Placement Financing of Up to $104.5 Million – Secures Orphan Drug Designations for QRX003 for Netherton Syndrome (NS) in the U.S. and Europe – Advances Proposed Expedited Regulatory Approval Pathways in Japan and Saudi Arabia and Secures Fast Track Designati |
|
| March 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2026 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissi |
|
| March 11, 2026 |
Exhibit 99.1 Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome — Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need — — QRX003 lotion (4%) currently being evaluated in two late-stage whole-body clinical trials for treatment of |
|
| January 20, 2026 |
Exhibit 99.1 Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome If granted, QRX003 could be approved for sale and reimbursement in Saudi Arabia as a treatment for Netherton Syndrome in 2H 2026 QRX003 could become the first ever approved treatment for Netherton Syndrome ASHBURN, Va., Jan. 20, 2026 (GLOBE NEWSWIRE) - Quoin Pharm |
|
| January 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2026 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commis |
|
| December 5, 2025 |
10,045,455 American Depositary Shares Representing 351,590,925 Ordinary Shares Filed Pursuant to Rule 424(b)(3) Registration No. 333-291385 PROSPECTUS 10,045,455 American Depositary Shares Representing 351,590,925 Ordinary Shares This prospectus relates to the resale from time to time of up to 10,045,455 American Depositary Shares (“ADSs”) representing 351,590,925 ordinary shares, no par value per share (“Ordinary Shares”) of Quoin Pharmaceuticals Ltd. (the “Company” or “Quo |
|
| December 2, 2025 |
December 2, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| November 17, 2025 |
Exhibit 10.2 Name/Optionee: Number of [Shares/ADSs]: Exercise Price Per [Share/ADS]: Date of Grant: Vesting Commencement Date: Vesting Schedule: Expiration Date: Quoin Pharmaceuticals Ltd. 2025 Equity Incentive Plan NON-QUALIFIED STOCK OPTION GRANT NOTIFICATION LETTER This Grant Notification Letter (this “Agreement”) evidences a non-qualified stock option granted by Quoin Pharmaceuticals Ltd. (the |
|
| November 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commi |
|
| November 17, 2025 |
Exhibit 10.1 Name/Optionee: Number of [Shares/ADSs]: Exercise Price Per [Share/ADS]: Date of Grant: Vesting Commencement Date: Vesting Schedule: Expiration Date: Quoin Pharmaceuticals Ltd. 2025 Equity Incentive Plan INCENTIVE STOCK OPTION GRANT NOTIFICATION LETTER This Grant Notification Letter (this “Agreement”) evidences an incentive stock option granted by Quoin Pharmaceuticals Ltd. (the “Compa |
|
| November 12, 2025 |
Exhibit 99.1 Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies Target Loadings of 4% and 5% Rapamycin Achieved for Topical Lotion and Dermal Patch Delivery Technologies Respectively Clinical Trial and Stability Batch Manufacture to Commence in Q4 2025 Clinical Testing in a Number of Indications Including Microcystic Lymphatic |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commi |
|
| November 7, 2025 |
As filed with the Securities and Exchange Commission on November 7, 2025 As filed with the Securities and Exchange Commission on November 7, 2025 Registration Statement No. |
|
| November 7, 2025 |
Calculation of Filing Fee Tables S-3 Quoin Pharmaceuticals, Ltd. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37846 QUOIN PHARMACEUTICALS LTD. |
|
| November 6, 2025 |
Exhibit 99.1 Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results - Private Placement Financing of Up to $105.3 Million Closed in October 2025 to Fund Operations and R&D - Sally Lawlor Appointed CFO to Support Commercialization and Financial Operations - Orphan Drug Designation Awarded by FDA to QRX003 for Netherton Syndrome - Pediatric Netherton Clinical Progr |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commis |
|
| October 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commis |
|
| October 21, 2025 |
Exhibit 99.1 Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome Upon Approval of NDA Quoin Will Receive Seven Years Marketing Exclusivity for QRX003 in the US Orphan Drug Designation previously granted by the European Medicines Agency in May 2025 ASHBURN, Va., Oct. 21, 2025 (GLOBE NEWSWIRE) - Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” o |
|
| October 15, 2025 |
Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED, SOLD, PLEDGED, OR OTHERWISE DISTRIBUTED OR TRA |
|
| October 15, 2025 |
Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED, SOLD, PLEDGED, OR OTHERWISE DISTRIBUTED OR TRA |
|
| October 15, 2025 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of October 10, 2025, between Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuan |
|
| October 15, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 10, 2025, between Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject |
|
| October 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commis |
|
| October 15, 2025 |
Exhibit 4.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED, SOLD, PLEDGED, OR OTHERWISE DISTRIBUTED OR TRA |
|
| October 15, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED, SOLD, PLEDGED, OR OTHERWISE DISTRIBUTED OR TRA |
|
| October 15, 2025 |
Exhibit 99.1 Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million PIPE financing included participation from leading healthcare-focused institutional investors including AIGH Capital Management, Soleus Capital, Nantahala Capital, Diadema Partners, Stonepine Capital Management, ADAR1 Capital Management, and Velan Capital, among others ASHBURN, Va., Oct. 10, 2025 (GLOB |
|
| October 15, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED, SOLD, PLEDGED, OR OTHERWISE DISTRIBUTED OR TRA |
|
| August 27, 2025 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Quoin Pharmaceuticals, Ltd. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Ordinary shares, no par value per share ("Ordinary Shares"), represented by American Depositary Shares (" |
|
| August 27, 2025 |
Quoin Pharmaceuticals Ltd. 2025 Equity Incentive Plan Exhibit 4.4 Quoin Pharmaceuticals Ltd. 2025 Equity Incentive Plan PURPOSE; TYPES OF AWARDS; CONSTRUCTION. 1.1. Purpose. The purpose of the Quoin Pharmaceuticals Ltd. 2025 Equity Incentive Plan (as amended, this “Plan”) is to provide an incentive to Service Providers of Quoin Pharmaceuticals Ltd., an Israeli company (together with any successor corporation thereto, the “Company”), or any Affiliate |
|
| August 27, 2025 |
As filed with the Securities and Exchange Commission on August 27, 2025 As filed with the Securities and Exchange Commission on August 27, 2025 Registration No. |
|
| August 27, 2025 |
Exhibit 10.1 This Agreement is dated as of August 15, 2025 Parties: (1) Gordon Dunn of XXXXXXXXX (the Employee/you); and (2) Quoin Pharmaceuticals, Inc. a Delaware corporation with registered number SR 20181693856 whose principal place of business is at 42127 Pleasant Forest Court, Ashburn, VA 20148 (the Company/we/us, and, together with all other affiliated companies, including Quoin Pharmaceutic |
|
| August 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commiss |
|
| August 25, 2025 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Quoin Pharmaceuticals, Ltd. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Ordinary shares, no par value per share ("Ordinary Shares"), represented by American Depositary Shares (" |
|
| August 25, 2025 |
As filed with the Securities and Exchange Commission on August 25, 2025 As filed with the Securities and Exchange Commission on August 25, 2025 Registration No. |
|
| August 21, 2025 |
Dated the 18th day of August 2025 Quoin Therapeutics (Ireland) Ltd SALLY LAWLOR SERVICE AGREEMENT Exhibit 10.1 Dated the 18th day of August 2025 Quoin Therapeutics (Ireland) Ltd and SALLY LAWLOR SERVICE AGREEMENT CONTENTS 1 INTERPRETATION 3 2 APPOINTMENT 5 3 WARRANTY 6 4 DUTIES 6 5 EXCLUSIVITY OF SERVICE 6 6 PLACE OF WORK 7 7 NO OBLIGATION TO PROVIDE WORK 7 8 SALARY 7 9 EXPENSES 8 10 PENSION AND OTHER BENEFITS 8 11 ANNUAL LEAVE 8 12 INCAPACITY 9 13 USE OF INTELLECTUAL PROPERTY 10 14 DISCIPLINE |
|
| August 21, 2025 |
Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy August 18, 2025 ASHBURN, Va. |
|
| August 21, 2025 |
Exhibit 3.1 Form of Amendment to the Articles The Companies Law, 5759-1999 Quoin Pharmaceuticals Ltd., Company No. 52-003648-4 (the “Company”) Amendment to the Company's Articles of Association (the “Articles”) adopted at the Company's Annual General Meeting If approved at the Annual Meeting, Section 4 of Part One of the Articles of Association will be mended to read as follows (additions are bold |
|
| August 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commiss |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissi |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37846 QUOIN PHARMACEUTICALS LTD. |
|
| August 7, 2025 |
Exhibit 99.1 Quoin Pharmaceuticals Announces Second Quarter 2025 Financial Results and Corporate Update - Positive 6 Month Clinical Data Reported for Ongoing Pediatric Netherton Syndrome Study - FDA Clears Second Pivotal Study of QRX003 for Netherton Syndrome - Initial Positive Data Announced from Peeling Skin Syndrome Pediatric Study - Orphan Drug Designation Granted by European Medicines Agency |
|
| July 17, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt |
|
| July 17, 2025 |
2024 Annual Report to Shareholders Quoin Pharmaceuticals Ltd. Effective April 9, 2025, the ratio of ADSs evidencing ordinary shares changed from 1 ADS representing one (1) ordinary share to 1 ADS representing thirty-five (35) ordinary shares, which resulted in a 1 for 35 reverse split of the issued and outstanding ADSs (the “Reverse Split”). Our Annual Report on Form 10-K for the year ended Decemb |
|
| July 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commission |
|
| July 7, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt |
|
| June 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissio |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissio |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commission |
|
| May 23, 2025 |
Exhibit 99.1 Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study · Study CL-QRX003-002 will test whole-body application of QRX003 in conjunction with off-label systemic therapy in approximately 12-15 subjects. · Study CL-QRX003-002 complements first whole-body pivotal study, CL-QRX003-003, being led by Dr. Amy Paller at North |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commission |
|
| May 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commission |
|
| May 21, 2025 |
Exhibit 99.1 Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome Company continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients Regulatory milestone provides 10 years of market exclusivity in Europe upon approval ASHBURN, Va., May 20, 2025 (GLOBE NEWSWIRE) - Quoin Pharmac |
|
| May 14, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commission |
|
| May 14, 2025 |
Exhibit 99.1 Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results May 13, 2025 Continued Progress in Ongoing Late-Stage Netherton Syndrome Studies Announced Positive Clinical Data for Adult and Pediatric Netherton Patients Provided Clear Visual Evidence of QRX003 Mechanism of Action Patent Portfolio Expanded to Support Pipeline Growth Launch of NETHERT |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37846 QUOIN PHARMACEUTICALS LTD. |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissi |
|
| April 4, 2025 |
Material Modification to Rights of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissio |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissio |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissio |
|
| March 28, 2025 |
As filed with the Securities and Exchange Commission on March 28, 2025. As filed with the Securities and Exchange Commission on March 28, 2025. Registration No. 333- 277016 Registration No. 333- 266476 Registration No. 333- 269543 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT NO. 333- 277016 UNDER THE SECURITIES ACT OF 1933 AND POST-EFFECTIVE AMENDMENT NO. 3 TO FORM S-1 REGISTR |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissi |
|
| March 20, 2025 |
Letter from Marcum LLP, dated March 20, 2025, addressed to the Securities and Exchange Commission Exhibit 16.1 March 20, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Quoin Pharmaceuticals Ltd. under Item 4.01 of its Form 8-K dated March 20, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Quoin Pharmaceuticals Ltd. |
|
| March 13, 2025 |
Exhibit 4.15 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of the date of this Annual Report on Form 10-K, Quoin Pharmaceuticals, Ltd., an Israeli company (“we,” “our” and the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: American Depositary |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissi |
|
| March 13, 2025 |
Exhibit 10.45 Compensation Program for Dr. Michael Myers At the 2024 annual meeting of shareholders, the Company’s shareholders approved a compensation program for the Company’s Chief Executive Officer and Chairman of the Board, Dr. Michael Myers. The program sets forth the following compensation limitations applicable to Dr. Myers which the Compensation Committee and the Board can utilize in sett |
|
| March 13, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37846 QUOIN P |
|
| March 13, 2025 |
Exhibit 3.1 PUBLIC COMPANY COMPANIES LAW, 5759–1999 A COMPANY LIMITED IN SHARES AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF QUOIN PHARMACEUTICALS LTD (PUBLIC CORPORATION 52-003648-4) Index Part One: Preamble 1 1. Name of the Company 1 2. Objectives of the Company 1 3. Liability of the shareholders 1 4. The capital 1 Part Two: General Provisions 1 5. Definitions and interpretation 1 6. Change o |
|
| March 13, 2025 |
Exhibit 99.1 Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results ASHBURN, Va., March 13, 2025 (GLOBE NEWSWIRE) – Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced recent corporate accomplishments and provided an |
|
| March 13, 2025 |
Non-Employee Directors’ Compensation Program, as amended Exhibit 10.44 Non-Employee Directors’ Compensation Program, as amended Each non-employee director of Quoin Pharmaceuticals Ltd. is entitled to receive as compensation for their service (i) an annual cash retainer of $82,500, (ii) an annual option grant having a value of no less than $20,000 and no more than $60,000, with such value being determined annually at the discretion of the Compensation Co |
|
| March 13, 2025 |
Quoin Pharmaceuticals Ltd. Insider Trading Policy Exhibit 19.1 Quoin Pharmaceuticals Ltd. Insider Trading Policy This Insider Trading Policy (“Policy”) provides the standards of Quoin Pharmaceuticals Ltd. (“Quoin” or the “Company”) with respect to transactions in securities of the Company and the handling of confidential information about Quoin and the companies with which Quoin does business. The federal securities laws prohibit insider trading. |
|
| March 13, 2025 |
Exhibit 10.46 Compensation Program for Denise Carter At the 2024 annual meeting of shareholders, the Company’s shareholders approved a compensation program for the Company’s Chief Operating Officer and a Member of the Board, Denise Carter. The program sets forth the following compensation limitations applicable to Ms. Carter which the Compensation Committee and the Board can utilize in setting Ms. |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commi |
|
| February 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commis |
|
| January 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commis |
|
| January 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commis |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2025 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commiss |
|
| January 2, 2025 |
Exhibit 99.1 Annex A The Reporting Person currently has the following outstanding options pursuant to the Issuer’s equity plans: Date of option grant Number of shares Exercise Price Per Share Vesting Schedule Expiration Date Portion Vested at 12/23/2024 4/12/2022 7,143 $210 Vests in four equal annual installments beginning on April 12, 2023. 04/12/2032 3,572 10/26/2023 80,966 $5.75 Vests in four a |
|
| January 2, 2025 |
Exhibit 99.1 Annex A The Reporting Person currently has the following outstanding options pursuant to the Issuer’s equity plans: Date of option grant Number of shares Exercise Price Per Share Vesting Schedule Expiration Date Portion Vested at 12/23/2024 4/12/2022 7,143 $210 Vests in four equal annual installments beginning on April 12, 2023. 04/12/2032 3,572 10/26/2023 80,965 $5.75 Vests in four a |
|
| December 26, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2024 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commi |
|
| December 26, 2024 |
Exhibit 1.1 December 20, 2024 Quoin Pharmaceuticals Ltd. Attention: Gordon Dunn 42127 Pleasant Forest Court Ashburn, VA 20148-7349 Dear Mr. Gordon Dunn: Subject to the terms and conditions of this letter agreement (the "Agreement") between Maxim Group LLC, as the lead placement agent ("Maxim") (Maxim is also referred to herein as the "Placement Agent"), and Quoin Pharmaceuticals Ltd., a company or |
|
| December 26, 2024 |
Exhibit 4.2 FORM OF SERIES F WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES Quoin Pharmaceuticals Ltd. Warrant ADSs: Initial Exercise Date: December 23, 2024 THIS SERIES F WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms |
|
| December 26, 2024 |
Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering Exhibit 99.1 Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering ASHBURN, Va., Dec. 20, 2024 (GLOBE NEWSWIRE) - Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announced the pricing of its “reasonable best efforts” public offering of 15,111,110 ordinary shares rep |
|
| December 26, 2024 |
Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES Quoin Pharmaceuticals Ltd. Warrant ADSs: Initial Exercise Date: December 23, 2024 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and s |
|
| December 26, 2024 |
Exhibit 4.3 FORM OF SERIES G WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES Quoin Pharmaceuticals Ltd. Warrant ADSs: Initial Exercise Date: December 23, 2024 THIS SERIES G WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subje |
|
| December 26, 2024 |
Exhibit 4.4 FORM OF AMENDMENT TO WarrantS to purchase ordinary shares represented by american depositary shares This AMENDMENT TO WARRANTS TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (this “Amendment”) is entered into as of December 20, 2024, by and between Quoin Pharmaceuticals Ltd., a corporation incorporated under the laws of Israel (the “Company”), and [·] (the “Holde |
|
| December 26, 2024 |
Exhibit 10.1 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 20, 2024, between Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, |
|
| December 23, 2024 |
Filed pursuant to Rule 424(b)(4) Registration No. 333-283734 3,137,778 Ordinary Shares Represented by American Depositary Shares 11,973,332 Pre-Funded Warrants to Purchase 11,973,332 Ordinary Shares Represented by American Depositary Shares 15,111,110 Series F Warrants to Purchase Up to 15,111,110 Ordinary Shares Represented by American Depositary Shares 15,111,110 Series G Warrants to Purchase Up |
|
| December 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2024 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commi |
|
| December 18, 2024 |
As filed with the Securities and Exchange Commission on December 18, 2024 As filed with the Securities and Exchange Commission on December 18, 2024 Registration No. |
|
| December 17, 2024 |
December 17, 2024 Michael Myers Chief Executive Officer Quoin Pharmaceuticals Ltd. |
|
| December 17, 2024 |
42127 Pleasant Forest Court Ashburn, VA 20148-7349 42127 Pleasant Forest Court Ashburn, VA 20148-7349 December 17, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| December 11, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-277016 PROSPECTUS SUPPLEMENT NO. 5 (to Prospectus dated April 3, 2024) 10,242,092 Ordinary Shares Represented by 10,242,092 American Depositary Shares Issuable Upon Exercise of the Pre-Funded Warrants, Common Warrants, Series D Warrants and Series E Warrants This prospectus supplement updates, amends and supplements the prospectus contained in |
|
| December 11, 2024 |
Form of Securities Purchase Agreement. Exhibit 10.42 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2024, between Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the te |
|
| December 11, 2024 |
Form of Placement Agency Agreement. Exhibit 1.1 [ ], 2024 Quoin Pharmaceuticals Ltd. Attention: Gordon Dunn 42127 Pleasant Forest Court Ashburn, VA 20148-7349 Dear Mr. Gordon Dunn: Subject to the terms and conditions of this letter agreement (the "Agreement") between Maxim Group LLC, as the lead placement agent ("Maxim") (Maxim is also referred to herein as the "Placement Agent"), and Quoin Pharmaceuticals Ltd., a company organized |
|
| December 11, 2024 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) QUOIN PHARMACEUTICALS LTD. |
|
| December 11, 2024 |
Exhibit 4.10 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES Quoin Pharmaceuticals Ltd. Warrant ADSs: Initial Exercise Date: , 2024 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limi |
|
| December 11, 2024 |
Exhibit 4.12 SERIES G WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES Quoin Pharmaceuticals Ltd. Warrant ADSs: Initial Exercise Date: , 2024 THIS SERIES G WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitati |
|
| December 11, 2024 |
As filed with the Securities and Exchange Commission on December 11, 2024 As filed with the Securities and Exchange Commission on December 11, 2024 Registration No. |
|
| December 11, 2024 |
Exhibit 4.11 SERIES F WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES Quoin Pharmaceuticals Ltd. Warrant ADSs: Initial Exercise Date: , 2024 THIS SERIES F WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to th |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2024 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commis |
|
| December 10, 2024 |
Exhibit 3.1 Form of Amendment to the Articles The Companies Law, 5759-1999 Quoin Pharmaceuticals Ltd., Company No. 52-003648-4 (the “Company”) Amendment to the Company's Articles of Association (the “Articles”) adopted at the Company's Annual General Meeting Section 19 of the Articles of Association is amended as follows (additions in underline and deletions in strikethrough): 19. Special General |
|
| November 14, 2024 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the American Depositary Shares of Quoin Pharmaceuticals Ltd. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13 |
|
| November 14, 2024 |
SC 13G/A 1 sch13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Quoin Pharmaceuticals Ltd. (Name of Issuer) American Depositary Shares (Title of Class of Securities) 74907L300 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to d |
|
| November 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 QUOIN PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) |
|
| November 8, 2024 |
424B3 1 tm2427874d2424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-277016 PROSPECTUS SUPPLEMENT NO. 4 (to Prospectus dated April 3, 2024) 10,242,092 Ordinary Shares Represented by 10,242,092 American Depositary Shares Issuable Upon Exercise of the Pre-Funded Warrants, Common Warrants, Series D Warrants and Series E Warrants This prospectus supplement updates, amends and suppl |
|
| November 8, 2024 |
Exhibit 99.1 Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results Quoin Initiates Peeling Skin Syndrome Clinical Program Further Expansion of International Reach for Netherton Syndrome Clinical Trials Significant Insider Share Purchases by the Entire Management Team ASHBURN, Va., Nov. 07, 2024 (GLOBE NEWSWIRE) - Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37846 QUOIN PHARMACEUTICALS LTD. |
|
| October 31, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2024 QUOIN PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) |
|
| October 24, 2024 |
2023 Annual Report to Shareholders Quoin Pharmaceuticals Ltd. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ցց ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or տտ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the tra |
|
| October 24, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt |
|
| October 11, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt |
|
| September 30, 2024 |
Other Events, Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2024 QUOIN PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 QUOIN PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (C |
|
| August 14, 2024 |
Exhibit 99.1 Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results Quoin Broadens Product Portfolio through Research Agreement with University College Cork, Ireland Company Expands On-going Clinical Trials in Netherton Syndrome to Include International Sites Announced Plans to Initiate Clinical Study in Peeling Skin Syndrome Continues to Evaluate M&A O |
|
| August 12, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-277016 PROSPECTUS SUPPLEMENT NO. 3 (to Prospectus dated April 3, 2024) 10,242,092 Ordinary Shares Represented by 10,242,092 American Depositary Shares Issuable Upon Exercise of the Pre-Funded Warrants, Common Warrants, Series D Warrants and Series E Warrants This prospectus supplement updates, amends and supplements the prospectus contained in |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37846 QUOIN PHARMACEUTICALS LTD. |
|
| May 10, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-277016 PROSPECTUS SUPPLEMENT NO. 2 (to Prospectus dated April 3, 2024) 10,242,092 Ordinary Shares Represented by 10,242,092 American Depositary Shares Issuable Upon Exercise of the Pre-Funded Warrants, Common Warrants, Series D Warrants and Series E Warrants This prospectus supplement updates, amends and supplements the prospectus contained in |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37846 QUOIN PHARMACEUTICALS LTD. |
|
| May 8, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-277016 PROSPECTUS SUPPLEMENT NO. 1 (to Prospectus dated April 3, 2024) 10,242,092 Ordinary Shares Represented by 10,242,092 American Depositary Shares Issuable Upon Exercise of the Pre-Funded Warrants, Common Warrants, Series D Warrants and Series E Warrants This prospectus supplement updates, amends and supplements the prospectus contained in |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2024 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissi |
|
| April 9, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2024 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissio |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement. ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)). ¨ Definiti |
|
| March 29, 2024 |
As filed with the Securities and Exchange Commission on March 29, 2024. Table of Contents As filed with the Securities and Exchange Commission on March 29, 2024. |
|
| March 14, 2024 |
Exhibit 4.19 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of the date of this Annual Report on Form 10-K, Quoin Pharmaceuticals, Ltd., an Israeli company (“we,” “our” and the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: American Depositary |
|
| March 14, 2024 |
Exhibit 97.1 QUOIN PHARMACEUTICALS LTD. COMPENSATION RECOVERY POLICY 1. Purpose. The purpose of this compensation recovery policy (the “Policy”) of Quoin Pharmaceuticals Ltd. (the “Company”) is to enable the Company to recover reasonably promptly the amount of any Erroneously Awarded Compensation in the event that the Company is required to prepare an Accounting Restatement. This Policy is designe |
|
| March 14, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37846 QUOIN P |
|
| March 13, 2024 |
Exhibit 99.1 Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical endpoints Eligibility age for enrollment into both studies has been lowered to four |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2024 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissi |
|
| March 8, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-277016 PROSPECTUS SUPPLEMENT (to Prospectus dated March 4, 2024) 811,250 Ordinary Shares Represented by 811,250 American Depositary Shares 3,251,250 Pre-Funded Warrants to Purchase 3,251,250 Ordinary Shares Represented by American Depositary Shares 4,062,500 Series D Warrants to Purchase 4,062,500 Ordinary Shares Represented by American Deposit |
|
| March 8, 2024 |
Exhibit 4.1 PRE-FUNDED warrant To purchase ordinary shares represented by american depositary shares Quoin Pharmaceuticals Ltd. Warrant ADSs: Initial Exercise Date: [●], 2024 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the |
|
| March 8, 2024 |
Exhibit 99.1 Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies Clearance to include teen patients in both the company’s open label and placebo controlled studies expected to significantly expand the number of eligible subjects, potentially expedite recruitment and lead to a more robust data set This important development re |
|
| March 8, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2024, between Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the ter |
|
| March 8, 2024 |
Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering Exhibit 99.2 Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering ASHBURN, Va., March 05, 2024 (GLOBE NEWSWIRE) - Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced the pricing of its "reasonable best efforts" public offering of 4,062,500 ordinary shares represented by 4,06 |
|
| March 8, 2024 |
Exhibit 1.1 [ ], 2024 Quoin Pharmaceuticals Ltd. Attention: Gordon Dunn 42127 Pleasant Forest Court Ashburn, VA 20148-7349 Dear Mr. Gordon Dunn: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the lead placement agent (“A.G.P.”) (A.G.P. is also referred to herein as the “Placement Agent”), and Quoin Pharmaceuticals Ltd., a |
|
| March 8, 2024 |
Exhibit 4.3 Series E - WARRANT to purchase ordinary shares represented by american depositary shares Quoin Pharmaceuticals Ltd. Warrant ADSs: Initial Exercise Date: [●], 2024 Original Issuance Date: [●], 2024 THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the t |
|
| March 8, 2024 |
Exhibit 4.4 AMENDMENT TO WarrantS to purchase ordinary shares represented by american depositary shares This AMENDMENT TO WARRANTS TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (this “Amendment”) is entered into as of March [●], 2024, by and between Quoin Pharmaceuticals Ltd., a corporation incorporated under the laws of Israel (the “Company”), and [●] (the “Holder”). WHERE |
|
| March 8, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-269543 PROSPECTUS SUPPLEMENT NO. 14 (to Prospectus dated March 17, 2023) 863,333 Ordinary Shares Represented by 863,333 American Depositary Shares Issuable Upon Exercise of Common Warrants This prospectus supplement updates, amends and supplements the prospectus contained in our Post-Effective Amendment No. 1 to Form F-1 on Form S-1 and Post-Ef |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissio |
|
| March 8, 2024 |
Exhibit 4.2 Series D - WARRANT to purchase ordinary shares represented by american depositary shares Quoin Pharmaceuticals Ltd. Warrant ADSs: Initial Exercise Date: [●], 2024 Original Issuance Date: [●], 2024 THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the t |
|
| March 6, 2024 |
Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-277016 811,250 Ordinary Shares Represented by 811,250 American Depositary Shares 3,251,250 Pre-Funded Warrants to Purchase 3,251,250 Ordinary Shares Represented by American Depositary Shares 4,062,500 Series D Warrants to Purchase 4,062,500 Ordinary Shares Represented by American Depositary Shares 4,062,500 Series E Warrants t |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commi |
|
| March 4, 2024 |
Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-277016 The information in this preliminary prospectus is not complete and may be changed. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Preliminary Prospectus Subject to Completion, Dated |
|
| February 27, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| February 14, 2024 |
February 14, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jessica Ansart Re: Quoin Pharmaceuticals Ltd. Registration Statement on Form S-1 File No. 333-277016 Ladies and Gentlemen: In accordance with Rule 461 of the General Rules and Regulations promulgated under the Securities Act of 1933, as amended (t |
|
| February 14, 2024 |
42127 Pleasant Forest Court Ashburn, VA 20148-7349 42127 Pleasant Forest Court Ashburn, VA 20148-7349 February 14, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| February 13, 2024 |
Form of Placement Agency Agreement. Exhibit 1.1 [ ], 2024 Quoin Pharmaceuticals Ltd. Attention: Gordon Dunn 42127 Pleasant Forest Court Ashburn, VA 20148-7349 Dear Mr. Gordon Dunn: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the lead placement agent (“A.G.P.”) (A.G.P. is also referred to herein as the “Placement Agent”), and Quoin Pharmaceuticals Ltd., a |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 (e)(2)) ¨ Definitive Proxy Stat |
|
| February 13, 2024 |
US74907L2016 / QUOIN PHARMACEUTICALS LTD SPONSORED ADR / Lind Global Fund II LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Quoin Pharmaceuticals Ltd. (Name of Issuer) American Depositary Shares (Title of Class of Securities) 74907L201 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| February 13, 2024 |
As filed with the Securities and Exchange Commission on February 13, 2024 Table of Contents As filed with the Securities and Exchange Commission on February 13, 2024 Registration No. |
|
| February 13, 2024 |
United States securities and exchange commission logo February 13, 2024 Dr. Michael Myers Chief Executive Officer Quoin Pharmaceuticals, Ltd. 42127 Pleasant Forest Court Ashburn, VA 20148-7349 Re: Quoin Pharmaceuticals, Ltd. Registration Statement on Form S-1 Filed February 12, 2023 File No. 333-277016 Dear Dr. Michael Myers: This is to advise you that we have not reviewed and will not review your |
|
| February 13, 2024 |
Form of Securities Purchase Agreement. Exhibit 10.36 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2024, between Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the te |
|
| February 13, 2024 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the American Depositary Shares of Quoin Pharmaceuticals Ltd. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G. February 13, 2024 LIND GLOBAL FUND II LP By: Lind Global Partners II LLC its Gene |
|
| February 12, 2024 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) QUOIN PHARMACEUTICALS LTD. |
|
| February 12, 2024 |
Exhibit 4.17 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES QUOIN PHARMACEUTICALS LTD. Warrant ADSs: Initial Exercise Date: [•], 2024 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to th |
|
| February 12, 2024 |
Form of Series E Common Warrant Exhibit 4.19 SERIES E - WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES QUOIN PHARMACEUTICALS LTD. Warrant ADSs: Initial Exercise Date: [•], 2024 Original Issuance Date: [•], 2024 THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the |
|
| February 12, 2024 |
As filed with the Securities and Exchange Commission on February 12, 2024 Table of Contents As filed with the Securities and Exchange Commission on February 12, 2024 Registration No. |
|
| February 12, 2024 |
Form of Series D Common Warrant Exhibit 4.18 SERIES D - WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES QUOIN PHARMACEUTICALS LTD. Warrant ADSs: Initial Exercise Date: [•], 2024 Original Issuance Date: [•], 2024 THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the |
|
| January 31, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-269543 PROSPECTUS SUPPLEMENT NO. 12 (to Prospectus dated March 17, 2023) 863,333 Ordinary Shares Represented by 863,333 American Depositary Shares Issuable Upon Exercise of Common Warrants This prospectus supplement updates, amends and supplements the prospectus contained in our Post-Effective Amendment No. 1 to Form F-1 on Form S-1 and Post-Ef |
|
| January 30, 2024 |
Exhibit 10.1 PURCHASE AGREEMENT PURCHASE AGREEMENT (this “Agreement”), dated as of January 25, 2024 (the “Execution Date”), by and between QUOIN PHARMACEUTICALS LTD., an Israeli company (the “Company”), and ALUMNI CAPITAL LP, a Delaware limited partnership (the “Investor”). RECITALS WHEREAS, subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor |
|
| January 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commis |
|
| December 18, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-269543 PROSPECTUS SUPPLEMENT NO. 11 (to Prospectus dated March 17, 2023) 863,333 Ordinary Shares Represented by 863,333 American Depositary Shares Issuable Upon Exercise of Common Warrants This prospectus supplement updates, amends and supplements the prospectus contained in our Post-Effective Amendment No. 1 to Form F-1 on Form S-1 and Post-Ef |
|
| December 18, 2023 |
Exhibit 99.1 Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome Positive initial data and clean safety profile catalyze optimization plan Size of both ongoing clinical trials significantly increased Lower dose eliminated from blinded trial Dosing frequency changed to twice-daily from once-daily for both trials ASHBURN, Va., December 13, 20 |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2023 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commi |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commis |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37846 QUOIN PHARMACEUTICALS LTD. |
|
| November 9, 2023 |
Exhibit 99.1 Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results Company reported positive clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study Positive benefits were observed across a number of clinical endpoints including pruritus, Investigator skin scoring system and patient global assessment. No |
|
| November 9, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-269543 PROSPECTUS SUPPLEMENT NO. 10 (to Prospectus dated March 17, 2023) 863,333 Ordinary Shares Represented by 863,333 American Depositary Shares Issuable Upon Exercise of Common Warrants This prospectus supplement updates, amends and supplements the prospectus contained in our Post-Effective Amendment No. 1 to Form F-1 on Form S-1 and Post-Ef |
|
| November 7, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-269543 PROSPECTUS SUPPLEMENT NO. 9 (to Prospectus dated March 17, 2023) 51,800,000,000 Ordinary Shares Represented by 863,333 American Depositary Shares Issuable Upon Exercise of Common Warrants This prospectus supplement updates, amends and supplements the prospectus contained in our Post-Effective Amendment No. 1 to Form F-1 on Form S-1 and P |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2023 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commis |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2023 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commis |
|
| November 1, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-269543 PROSPECTUS SUPPLEMENT NO. 8 (to Prospectus dated March 17, 2023) 51,800,000,000 Ordinary Shares Represented by 863,333 American Depositary Shares Issuable Upon Exercise of Common Warrants This prospectus supplement updates, amends and supplements the prospectus contained in our Post-Effective Amendment No. 1 to Form F-1 on Form S-1 and P |
|
| October 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A NFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement. ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| September 14, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-269543 PROSPECTUS SUPPLEMENT NO. 7 (to Prospectus dated March 17, 2023) 51,800,000,000 Ordinary Shares Represented by 863,333 American Depositary Shares Issuable Upon Exercise of Common Warrants This prospectus supplement updates, amends and supplements the prospectus contained in our Post-Effective Amendment No. 1 to Form F-1 on Form S-1 and P |
|
| September 13, 2023 |
Exhibit 10.1 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(B)(10). SUCH EXCLUDED INFORMATION IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXCLUSIVE LICENSE AND DISTRIBUTION AGREEMENT (version 28 July 2023) This License and Distribution Agreement (this “Agreement”), dated as of September 1, 2023 (“Eff |
|
| September 13, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commi |
|
| September 12, 2023 |
7DEOHRI&RQWHQWV 81,7('67$7(6 6(&85,7,(6$1'(;&+$1*(&200,66,21 :DVKLQJWRQ'& )250. |
|
| September 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37846 QUOIN PHARMACEUTICALS LTD. |
|
| August 3, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-269543 PROSPECTUS SUPPLEMENT NO. 6 (to Prospectus dated March 17, 2023) 51,800,000,000 Ordinary Shares Represented by 863,333 American Depositary Shares Issuable Upon Exercise of Common Warrants This prospectus supplement updates, amends and supplements the prospectus contained in our Post-Effective Amendment No. 1 to Form F-1 on Form S-1 and P |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissi |
|
| August 2, 2023 |
Exhibit 99.1 Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results Company reports positive clinical data for first subject to complete testing in ongoing open-label Netherton Syndrome study Subject’s skin was assessed to be fully clear by Investigator at QRX003 treatment areas Subject also demonstrated key improvements across all other clinical endpoi |
|
| July 18, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-269543 PROSPECTUS SUPPLEMENT NO. 5 (to Prospectus dated March 17, 2023) 51,800,000,000 Ordinary Shares Represented by 10,360,000 American Depositary Shares Issuable Upon Exercise of Common Warrants This prospectus supplement updates, amends and supplements the prospectus contained in our Post-Effective Amendment No. 1 to Form F-1 on Form S-1 an |
|
| July 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commiss |
|
| June 28, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-269543 PROSPECTUS SUPPLEMENT NO. 4 (to Prospectus dated March 17, 2023) 51,800,000,000 Ordinary Shares Represented by 10,360,000 American Depositary Shares Issuable Upon Exercise of Common Warrants This prospectus supplement updates, amends and supplements the prospectus contained in our Post-Effective Amendment No. 1 to Form F-1 on Form S-1 an |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissio |
|
| May 12, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-269543 PROSPECTUS SUPPLEMENT NO. 3 (to Prospectus dated March 17, 2023) 51,800,000,000 Ordinary Shares Represented by 10,360,000 American Depositary Shares Issuable Upon Exercise of Common Warrants This prospectus supplement updates, amends and supplements the prospectus contained in our Post-Effective Amendment No. 1 to Form F-1 on Form S-1 an |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commission |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37846 QUOIN PHARMACEUTICALS LTD. |
|
| May 9, 2023 |
424B3 1 tm2311915d2424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-269543 PROSPECTUS SUPPLEMENT NO. 2 (to Prospectus dated March 17, 2023) 51,800,000,000 Ordinary Shares Represented by 10,360,000 American Depositary Shares Issuable Upon Exercise of Common Warrants This prospectus supplement updates, amends and supplements the prospectus contained in our Post-Effective Amendme |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commission |
|
| May 8, 2023 |
Exhibit 99.1 Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results First patient dosed in Quoin’s single arm, open label clinical trial in Netherton Syndrome patients currently receiving off-label systemic therapy Recruitment and dosing continue in Quoin’s ongoing double blinded, placebo-controlled study of QRX003 for Netherton Syndrome Following succes |
|
| April 7, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-269543 PROSPECTUS SUPPLEMENT NO. 1 (to Prospectus dated March 17, 2023) 51,800,000,000 Ordinary Shares Represented by 10,360,000 American Depositary Shares Issuable Upon Exercise of the Common Warrants This prospectus supplement updates, amends and supplements the prospectus contained in our Post-Effective Amendment No. 1 to Form F-1 on Form S- |
|
| April 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2023 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissio |
|
| March 22, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333- 266476 Registration No. 333- 269543 Prospectus 51,800,000,000 Ordinary Shares Represented by 10,360,000 American Depositary Shares Issuable Upon Exercise of the Common Warrants This prospectus relates to the issuance by Quoin Pharmaceuticals Ltd. of 51,800,000,000 ordinary shares represented by 10,360,000 American Depositary Shares, or “ADSs,” |
|
| March 15, 2023 |
Description of Ordinary Shares. Exhibit 99.1 The following description of our securities registered pursuant to the Securities Exchange Act of 1934 is a summary of the material terms of our articles of association, Israeli corporate law and such securities. This description contains all material information concerning such securities but does not purport to be complete. DESCRIPTION OF ORDINARY SHARES Ordinary Shares As of March |
|
| March 15, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37846 QUOIN P |
|
| March 15, 2023 |
Exhibit 107 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Form Type) QUOIN PHARMACEUTICALS LTD. |
|
| March 15, 2023 |
Exhibit 14.1 QUOIN PHARMACEUTICALS LTD. CODE OF ETHICS AND BUSINESS CONDUCT I. INTRODUCTION This Code of Ethics and Business Conduct (this “Code”) contains general guidelines for conducting the business of Quoin Pharmaceuticals Ltd. and its subsidiaries (collectively, the “Company” or “Quoin”) and applies to all of the Company’s directors, officers and employees. We refer to all officers and other |
|
| March 15, 2023 |
As filed with the Securities and Exchange Commission on March 15, 2023 As filed with the Securities and Exchange Commission on March 15, 2023 Registration No. |
|
| March 15, 2023 |
As filed with the Securities and Exchange Commission on March 15, 2023. Table of Contents As filed with the Securities and Exchange Commission on March 15, 2023. |
|
| March 9, 2023 |
Exhibit 99.1 Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter And Full Year 2022 Financial Results · Quoin announced dosing of first patient in double blinded clinical study to evaluate QRX003 for Netherton Syndrome · Quoin announced initiation of a second clinical trial to evaluate QRX003 in Netherton Syndrome patients currently receiving off-label systemic therapy · C |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 92-2593104 (State or other jurisdiction of incorporation) (Commissio |
|
| March 3, 2023 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the American Depository Shares of Quoin Pharmaceuticals Ltd. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13 |
|
| March 3, 2023 |
US74907L2016 / QUOIN PHARMACEUTICALS LTD SPONSORED ADR / Lind Global Fund II LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Quoin Pharmaceuticals Ltd. (Name of Issuer) American Depository Shares (Title of Class of Securities) 74907L201 (CUSIP Number) February 24, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 28, 2023 |
Exhibit 10.2 February 22, 2023 Quoin Pharmaceuticals Ltd. Attention: Gordon Dunn Azrieli Center, Round Tower, 30th Floor 132 Menachem Begin Blvd Tel Aviv, 6701101 Dear Mr. Gordon Dunn: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the sole placement agent (“A.G.P.”) (A.G.P. is also referred to herein as the “Placement Age |
|
| February 28, 2023 |
Exhibit 4.2 WARRANT to purchase ordinary shares represented by american depositary shares Quoin Pharmaceuticals Ltd. Warrant ADSs: Initial Exercise Date: February 24, 2023 Original Issuance Date: February 24, 2023 THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon |
|
| February 28, 2023 |
Quoin Pharmaceuticals Announces Pricing of $7.0 Million Public Offering Exhibit 99.1 Quoin Pharmaceuticals Announces Pricing of $7.0 Million Public Offering ASHBURN, Va., February 22, 2023 (GLOBE NEWSWIRE) - Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announced the pricing of its "reasonable best efforts" public offering of 24,750,000,000 ordinary sh |
|
| February 28, 2023 |
Exhibit 4.3 AMENDMENT NO. 1 TO Warrant to purchase ordinary shares represented by american depositary shares This AMENDMENT NO. 1 TO WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (this “Amendment”) is entered into as of February 24, 2023, by and between Quoin Pharmaceuticals Ltd., a corporation incorporated under the laws of Israel (the “Company”), and [●] (the “Hol |
|
| February 28, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 22, 2023, between Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject |
|
| February 28, 2023 |
Filed pursuant to Rule 424(b)(3) SEC File No. 333-266476 PROSPECTUS SUPPLEMENT NO. 7 (to Prospectus dated August 5, 2022) 11,050,000,000 Ordinary Shares Represented by 2,210,000 American Depositary Shares Pre-Funded Warrants to Purchase 5,750,000,000 Ordinary Shares Represented by 1,150,000 American Depositary Shares Common Warrants to Purchase 16,800,000,000 Ordinary Shares Represented by 3,360,0 |
|
| February 28, 2023 |
6,435,548,000 Ordinary Shares Represented by 1,287,110 American Depositary Shares Filed pursuant to Rule 424(b)(3) SEC File No. 333-264305 PROSPECTUS SUPPLEMENT NO. 13 (to Prospectus dated April 22, 2022) 6,435,548,000 Ordinary Shares Represented by 1,287,110 American Depositary Shares This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form F-1, effective as of April 22, 2022 (as supplemented or amended from time |
|
| February 28, 2023 |
Filed pursuant to Rule 424(b)(3) SEC File No. 333-269543 PROSPECTUS SUPPLEMENT NO. 1 (to Prospectus dated February 22, 2023) 24,750,000,000 Ordinary Shares Represented by 4,950,000 American Depositary Shares Pre-Funded Warrants to Purchase 10,250,000,000 Ordinary Shares Represented by 2,050,000 American Depositary Shares Common Warrants to Purchase 35,000,000,000 Ordinary Shares Represented by 7,0 |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) State of Israel 001-37846 n/a (State or other jurisdiction of incorporation) (Commission F |
|
| February 28, 2023 |
Exhibit 4.1 PRE-FUNDED warrant To purchase ordinary shares represented by american depositary shares Quoin Pharmaceuticals Ltd. Warrant ADSs: Initial Exercise Date: February 24, 2023 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subjec |
|
| February 23, 2023 |
Table of Contents Prospectus Filed Pursuant to Rule 424(b)(4) Registration No. 333-269543 24,750,000,000 Ordinary Shares Represented by 4,950,000 American Depositary Shares Pre-Funded Warrants to Purchase 10,250,000,000 Ordinary Shares Represented by 2,050,000 American Depositary Shares Common Warrants to Purchase 35,000,000,000 Ordinary Shares Represented by 7,000,000 American Depositary Shares 1 |
|
| February 14, 2023 |
CUSIP No: 74907L201 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Quoin Pharmaceuticals Ltd. (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) 74907L201 (CUSIP Number) Dece |
|
| February 14, 2023 |
US74907L2016 / QUOIN PHARMACEUTICALS LTD SPONSORED ADR / GOLDMAN SACHS GROUP INC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* QUOIN PHARMACEUTICALS, LTD. - (Name of Issuer) American Depositary Shares, each representing 5,000 Ordinary Shares, no par value per share - (Title of Class of Securities) 74907L201 - (CUSIP Number) December 30, 2022 - (Date of Event Which Requires Filin |
|
| February 9, 2023 |
CORRESP 1 filename1.htm February 9, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Quoin Pharmaceuticals Ltd. Registration Statement on Form S-1 File No. 333-269543 Ladies and Gentlemen: In accordance with Rule 461 of the General Rules and Regulations promulgated under the Securities Act of 1933, as amended (the |
|
| February 9, 2023 |
As filed with the Securities and Exchange Commission on February 8, 2023. Table of Contents As filed with the Securities and Exchange Commission on February 8, 2023. |
|
| February 9, 2023 |
Quoin Pharmaceuticals Ltd. 42127 Pleasant Forest Court Ashburn, VA 20148-7349 Quoin Pharmaceuticals Ltd. 42127 Pleasant Forest Court Ashburn, VA 20148-7349 February 9, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 RE: Quoin Pharmaceuticals Ltd. Registration Statement on Form S-1 Registration No. 333-269543 Ladies and Gentlemen: Quoin Pharmaceuticals Ltd. (the “Company”) hereby reques |
|
| February 9, 2023 |
Exhibit 107 FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Form Type) QUOIN PHARMACEUTICALS LTD. |
|
| February 8, 2023 |
February 8, 2023 VIA EDGAR Division of Corporation Finance Office of Industrial Applications and Services U. |
|
| February 7, 2023 |
United States securities and exchange commission logo February 7, 2023 Dr. Michael Myers Chief Executive Officer Quoin Pharmaceuticals, Ltd. 42127 Pleasant Forest Court Ashburn, VA 20148-7349 Re: Quoin Pharmaceuticals, Ltd. Registration Statement on Form S-1 Filed February 3, 2023 File No. 333-269543 Dear Dr. Michael Myers: We have limited our review of your registration statement to those issues |
|
| February 3, 2023 |
Exhibit 4.15 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES QUOIN PHARMACEUTICALS LTD. Warrant ADSs: Initial Exercise Date: [•], 2023 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to th |
|
| February 3, 2023 |
As filed with the Securities and Exchange Commission on February 2, 2023. Table of Contents As filed with the Securities and Exchange Commission on February 2, 2023. |
|
| February 3, 2023 |
Form of Securities Purchase Agreement. Exhibit 4.14 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [•], 2023, between Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the |
|
| February 3, 2023 |
Exhibit 4.16 WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES QUOIN PHARMACEUTICALS LTD. Warrant ADSs: Initial Exercise Date: [•], 2023 Original Issuance Date: [•], 2023 THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and s |
|
| February 3, 2023 |
Form of Placement Agency Agreement. Exhibit 1.1 [•], 2023 Quoin Pharmaceuticals Ltd. Attention: Gordon Dunn Azrieli Center, Round Tower, 30th Floor 132 Menachem Begin Blvd Tel Aviv, 6701101 Dear Mr. Gordon Dunn: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the sole placement agent (“A.G.P.”) (A.G.P. is also referred to herein as the “Placement Agent”), and |
|
| February 3, 2023 |
Exhibit 107 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Form Type) QUOIN PHARMACEUTICALS LTD. |
|
| November 10, 2022 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes, which are included elsewhere in this Form 6-K, and our audited consolidated financial statements a |
|
| November 10, 2022 |
Filed pursuant to Rule 424(b)(3) SEC File No. 333-266476 PROSPECTUS SUPPLEMENT NO. 6 (to Prospectus dated August 5, 2022) 11,050,000,000 Ordinary Shares Represented by 2,210,000 American Depositary Shares Pre-Funded Warrants to Purchase 5,750,000,000 Ordinary Shares Represented by 1,150,000 American Depositary Shares Common Warrants to Purchase 16,800,000,000 Ordinary Shares Represented by 3,360,0 |
|
| November 10, 2022 |
6,435,548,000 Ordinary Shares Represented by 1,287,110 American Depositary Shares Filed pursuant to Rule 424(b)(3) SEC File No. 333-264305 PROSPECTUS SUPPLEMENT NO. 12 (to Prospectus dated April 22, 2022) 6,435,548,000 Ordinary Shares Represented by 1,287,110 American Depositary Shares This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form F-1, effective as of April 22, 2022 (as supplemented or amended from time |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 (No. 2) Commission File Number 001-37846 QUOIN PHARMACEUTICALS LTD. (Translation of registrant’s name into English) Azrieli Center, Round Tower, 30th Floor 132 Menachem Begin Blvd |
|
| November 10, 2022 |
Table of Contents Exhibit 99.1 QUOIN PHARMACEUTICALS LTD. Condensed Consolidated Financial Statements as of September 30, 2022 and December 31, 2021 and for the three and nine months ended September 30, 2022 and 2021 (unaudited) Table of Contents QUOIN PHARMACEUTICALS LTD. Contents Page Condensed Consolidated Financial Statements (Unaudited) Consolidated Balance Sheets as of September 30, 2022 and |
|
| November 7, 2022 |
Filed pursuant to Rule 424(b)(3) SEC File No. 333-266476 PROSPECTUS SUPPLEMENT NO. 5 (to Prospectus dated August 5, 2022) 11,050,000,000 Ordinary Shares Represented by 2,210,000 American Depositary Shares Pre-Funded Warrants to Purchase 5,750,000,000 Ordinary Shares Represented by 1,150,000 American Depositary Shares Common Warrants to Purchase 16,800,000,000 Ordinary Shares Represented by 3,360,0 |
|
| November 7, 2022 |
EX-16.1 2 tm2229920d1ex16-1.htm EXHIBIT 16.1 Exhibit 16.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM November 7, 2022 Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Quoin Pharmaceuticals, LTD Commission File Number 001-37846 Commissioners: We have read the statements made by Quoin Pharmaceuticals, LTD of its Form 6-K dated November 7, 2022. We agree wi |
|
| November 7, 2022 |
6,435,548,000 Ordinary Shares Represented by 1,287,110 American Depositary Shares 424B3 1 tm2229920d3424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) SEC File No. 333-264305 PROSPECTUS SUPPLEMENT NO. 11 (to Prospectus dated April 22, 2022) 6,435,548,000 Ordinary Shares Represented by 1,287,110 American Depositary Shares This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form F-1, effective as of April 22, 2022 (a |
